Table 4 Impact of SF on antimicrobial therapy
No. | Age range, gender | POD, Surgery | Identified pathogen in SF | Identified pathogen in BC | Initial antimicrobial therapy | Adjustment of therapy | Outcome after adjustment of therapy |
|---|---|---|---|---|---|---|---|
1 | 50–59, 1 | 53, CABG, AVR, MVS | Aspergillus fumigatus | – | Meropenem, Vancomycin | Escalation with voriconazole | survived |
2 | 50–59, 1 | 38, LTX | Aspergillus fumigatus | – | Meropenem, Vancomycin, Fluconazole | Escalation with voriconazole, discontinuation of fluconazole | died |
3 | 70–79, 2 | CABG, AVR, MVS, TVS | Aspergillus fumigatus | – | Piperacilline/Tazobactam | Escalation with voriconazole | died |
4 | 50–59, 1 | 18, Aortic surgery | Candida albicans | Candida albicans | Ciprofloxacine, Vancomycin, Colistin | Escalation with caspofungin | died |
5 | 60–69, 2 | 33, AVR, MVS | Candida albicans | – | Meropenem, Vancomycin | Escalation with fluconazole | survived |
6 | 60–69, 1 | 47, AVR | Candida albicans | – | Linezolid, Imipenem | Escalation with caspofungin | survived |
7 | 70–79, 1 | 21. CABG, MVS, TVS | Enterococcus faecium | CoNS | Piperacilline/Tazobactam | Escalation with vancomycin | died |
8 | 20–29, 1 | 49. LTX | Pseudomonas aeruginosa | – | Vancomycin, Ceftazidime | Escalation with colistin | survived |